



Kubota Pharmaceutical Holdings Co., Ltd. Announces an Update to its Corporate Structure and Transition to a Company with an Audit and Supervisory Committee System

Tokyo (February 1, 2023) — Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo: 4596) (“Kubota Pharma” or the “Company”) announced that our Board of Directors has resolved at a meeting held today to transition the Company to include a new Audit and Supervisory Committee, subject to approval at the 8th Ordinary General Meeting of Shareholders to be held in April 2023, as follows:

Description

1. Purpose of Transition to a Company with an Audit and Supervisory Committee System

As a result of reexamining our Company’s corporate governance structure, we have come to the conclusion that having an Audit and Supervisory Committee is a more appropriate organizational design system that can ensure the same sound corporate governance as before and take into consideration our Company’s business scale and trends among other publicly-listed companies.

Specifically, by transitioning to a Company with an Audit and Supervisory Committee system, directors who are members of the audit committee and other directors are elected by shareholders in a different manner. This will separate directors who are directly entrusted by shareholders to execute business operations from directors who are audit committee members that will audit and supervise management from a more independent standpoint, thereby clarifying the division of responsibilities between management and oversight. As in the case of a company with a nomination committee, it will be possible to broadly delegate business execution decisions to directors by stipulating it in the articles of incorporation, which will allow for more efficient management decision-making. A company with an audit committee includes a process that can be easily understood on a global basis.

In order to further enhance corporate governance, the Company has decided to transition to a Company with an Audit and Supervisory Committee.

2. Timing of Transition to a Company with an Audit and Supervisory Committee

At the 8th Ordinary General Meeting of Shareholders scheduled to be held in April 2023, the necessary changes to the Articles of Incorporation will be approved. The Company will then transition to a Company with an Audit and Supervisory Committee.

3. Others

The changes to the Articles of Incorporation and the personnel changes of directors and corporate auditors in connection with this matter will be announced as soon as they are determined.

About Kubota Pharmaceutical Holdings Co., Ltd.

Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) is committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group’s pipeline includes a wearable

device for myopia control using Kubota Glass™ technology and a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients. <https://www.kubotaholdings.co.jp/en/>

Cautionary Statements

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include statements regarding our expectations related to our development plans and ability to successfully develop and commercialize our product candidates and the potential efficacy, future development plans and commercial potential of our product candidates. These statements are based on current assumptions that involve risks, uncertainties and other factors that could cause the actual results, events, or developments to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our investigational product candidates may not demonstrate the expected safety and efficacy; our pre-clinical development efforts may not yield additional product candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; our clinical trials could be delayed; new developments in the intensely competitive ophthalmic pharmaceutical market may require changes in our clinical trial plans or limit the potential benefits of our investigational product candidates; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. For a detailed discussion of the foregoing risks and other risk factors, please refer to our filings with the Securities and Exchange Commission, which are available on Kubota Pharmaceutical Holdings (Kubota Vision's parent company) investor relations website (<https://www.kubotaholdings.co.jp/en/ir/>) and on the SEC's website (<http://www.sec.gov>).

“Kubota Vision,” the Kubota Vision logo and “Kubota” are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Media and Investor Relations Contact:

Press and Media Inquiries
Phone: +81-3-6550-8928
Email: pr@kubotaholdings.co.jp